The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of B7H3 CAR-T cells administered intracranially in recurrent glioblastoma.
 
Gordon Li
Research Funding - Novocure
 
Brian Stocksdale
No Relationships to Disclose
 
Kun-Wei Song
No Relationships to Disclose
 
Jasia Mahdi
No Relationships to Disclose
 
Kelly Tanner
No Relationships to Disclose
 
Sophie Bertrand
Stock and Other Ownership Interests - Intuitive Surgical
 
Michael Iv
Stock and Other Ownership Interests - Octave Bioscience
Honoraria - Imaging Biometrics
Consulting or Advisory Role - Octave Bioscience
Patents, Royalties, Other Intellectual Property - Royalties for Medical Book published by Thieme Medical Publishers
 
Zachary Threlkeld
Consulting or Advisory Role - Baim Institute for Clinical Research
 
Sneha Ramakrishna
No Relationships to Disclose
 
Bita Sahaf
No Relationships to Disclose
 
Emily Egeler
No Relationships to Disclose
 
Vivek Charu
No Relationships to Disclose
 
Ramya Tunuguntla
No Relationships to Disclose
 
Kate Therkelsen
No Relationships to Disclose
 
Seema Nagpal
Consulting or Advisory Role - Daiichi Sankyo/Lilly; EnClear Therapies; Novocure; SERVIER; Telix Pharmaceuticals
Research Funding - ABM (Inst); Berg Pharma (Inst); Novocure (Inst); SERVIER (Inst); VBI Vaccines (Inst)
Travel, Accommodations, Expenses - BPGBio
 
Michael Lim
Stock and Other Ownership Interests - Egret Bioscience
Honoraria - Accuray; Agenus; Bristol-Myers Squibb; InSightec; Merck; Oncorus; Stryker; tocagen
Consulting or Advisory Role - Biohaven Pharmaceuticals; Bristol-Myers Squibb; CraniUs; Egret Bioscience; Global Coalition for Adaptive Research; Hemispherian; Hoth Therapeutics; InCephalo Therapeutics/University of Zurich; Insightec; Mediflix; novocure; Noxxon Pharma; Pyramid Biosciences; Sanianoia; SERVIER; Stryker; VBI Vaccines
Research Funding - Accuray (Inst); Arbor Pharmaceuticals (Inst); Biohaven Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Combination of Immunotherapy with Local Chemotherapy for the Treatment of Malignancies. (Inst); CXCR6 as an Immuno-oncology Target to Improve T cell Metabolic Response (Inst); Meteorin-like (METRNL) as an Immuno-oncology Target (Inst); Methods of Treating Myocardial Infarction, Ischemia, and Ischemia Reperfusion Injury (Inst); Methods Patent for Combining Immunotherapy with Radiation (Inst); Modulation of Oxidative Stress as a Therapeutic Pathway in Trigeminal Neuralgia (Inst); Novel Immunotherapeutic Targets Identified in Patients with Glioblastoma using RNA Sequencing to Compare Gene Expression Patterns in Tumor Infiltrating (TIL) and Peripheral Blood Lymphocytes (Inst); Polyfunctional lymphocytes as a biomarker of antitumor activity (Inst); Post-surgical imaging marker: A marker for imaging includes a bio-dissolvable material and a contrast agent configured to provide contrast during an imaging procedure. (Inst); Program Death 1 (PD-1) Agonists for the Treatment of Cerebral Vasospasm (Inst); Sustained and Localized Antibody and Immunotherapeutic Delivery to Lymph Nodes (Inst); Universal Microport (Inst); Use of Anti-PD-1 Delivery with the Urogen® Polymer to Tumor Draining Lymph Nodes for Treatment of Cancers (Inst); Use of the ZMIZ1 Marker in Directing Treatment and Predicting Survival in Cancer. (Inst)
Travel, Accommodations, Expenses - Accuray; SERVIER; Stryker
 
Michelle Monje
Leadership - MapLight Therapeutics (I)
Stock and Other Ownership Interests - MapLight Therapeutics (I)
Patents, Royalties, Other Intellectual Property - I have patents or patent applications related to CAR T cell therapy for DIPG/DMG or to targeting neuron-glial interactions in disease states.; My husband has many patents related to optogenetics and its applications (I)
 
Brian Scott
Honoraria - Kite/Gilead
 
Crystal Mackall
Leadership - CARGO Therapeutics
Stock and Other Ownership Interests - CARGO Therapeutics; Ensoma; Link Cell Therapies; Lyell Immunopharma; Mammoth Biosciences
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; CARGO Therapeutics; Ensoma; GBM NewCo; immatics; Link Cell Therapies
Research Funding - Lyell Immunopharma; Tune Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - I am an inventor on a suite of patents licensed to CARGO Therapeutics from which I have received royalties from NIH and Stanford.; I am an inventor on numerous patents related to chimeric antigen receptor therapeutics and received royalties from NIH for the CD22-CAR patent licensed to Juno therapeutics.
Other Relationship - Lyell Immunopharma; Syncopation Life Sciences
 
Reena Thomas
Research Funding - Chimerix (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending